#BioconBiologics (@Bioconlimited) on Monday said it will acquire #Viatris global biosimilars business including their rights in partnered in-licensed portfolio.
The company is making the acquisition for up to $3.335 billion in stock and cash.@kiranshaw pic.twitter.com/HFrYBH4lhW— IANS Tweets (@ians_india) February 28, 2022
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


